MARKET

SBPH

SBPH

Spring Bk Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.080
-0.060
-5.26%
Closed 16:00 10/28 EDT
OPEN
1.120
PREV CLOSE
1.140
HIGH
1.120
LOW
1.050
VOLUME
46.42K
TURNOVER
--
52 WEEK HIGH
4.800
52 WEEK LOW
0.8000
MARKET CAP
18.65M
P/E (TTM)
-0.6172
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
We're A Little Worried About Spring Bank Pharmaceuticals' (NASDAQ:SBPH) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 10/01 17:49
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: BMC Stock Holdings, Inc. (Nasdaq - BMCH), Virtusa Corporation (Nasdaq - VRTU), Spring Bank Pharmaceuticals, Inc. (NasdaqGS - SBPH)
BALA CYNWYD, PA / ACCESSWIRE / September 29, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions.
ACCESSWIRE · 09/29 23:49
5 Penny Stocks To Watch With Recent & Upcoming Biotech Events
Penny Stocks To Watch If Biotech Is Your Focus This Week
Benzinga · 09/27 18:40
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Biotech stock reversed course last week, dragged lower by the broader market weakness.
Benzinga · 09/26 18:40
SBPH, CNXM, ONDK, and NETE SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
GlobeNewswire · 08/14 02:00
Spring Bank Q2 EPS $(0.38) Down From $(0.28) YoY
Spring Bank (NASDAQ:SBPH) reported quarterly losses of $(0.38) per share. This is a 35.71 percent decrease over losses of $(0.28) per share from the same period last year.
Benzinga · 08/10 20:00
SPRING BANK PARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Spring Bank Pharmaceuticals, Inc. - SBPH
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Spring Bank Pharmaceuticals, Inc. (NasdaqGS: SBPH) ("the Company") with F-star Therapeutics, Limited in
PR Newswire · 08/06 22:58
SPRING BANK PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger
WILMINGTON, Del., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Spring Bank Pharmaceuticals, Inc. (“Spring Bank”) (NASDAQ GS: SBPH) regarding possible breaches of fiduciary duties and other violations of law relate
GlobeNewswire · 08/04 13:42
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SBPH. Analyze the recent business situations of Spring Bk Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SBPH stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 6.76M
% Owned: 39.17%
Shares Outstanding: 17.27M
TypeInstitutionsShares
Increased
3
140.37K
New
7
-29.89K
Decreased
10
129.33K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SBPH
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Spring Bank Pharmaceuticals Inc stock information, including NASDAQ:SBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SBPH stock methods without spending real money on the virtual paper trading platform.